Shoeshine
Friday 14th November 2003 |
Text too small? |
The issues are old ones. First, the company didn't live up to the 2001 information memorandum ebitda (earnings before interest, tax, depreciation and amortisation) forecast of $18.3 million for the August 2002 year.
That's disappointing for everyone but in the context of a rocketing exchange rate, low beef prices for Tru-Test's customers and the Australian drought, it's scarcely surprising.
The Neuronz purchase has also aggravated some shareholders but, like the company's financial performance, that was known before last year's annual meeting, at which, apparently, no questions were asked.
The theory getting most traction is that someone is trying to unsettle shareholders and turn up the gas on Tru-Test's board and management to smooth the path of a takeover.
The natural candidate for the bidder is Skellmax Industries, whose largest shareholder, Axa Asia Pacific, has 5.67%.
It's a small country. Axa is also one of Tru-Test's shareholders.
No comments yet
Fletcher Building Announces Director Appointment
Meridian issues new demand response exercise notice to NZAS
CRP - Chatham Closes Private Placement of Shares
General Finance - Olympic Term Deposit Promotion featuring a Special Bonus of 0.1%
July 22nd Morning Report
VCT - Operational performance for the year ended 30 June 2024
Challenge to banks the way to go
Bigger returns or lower risk?
NPH - Director Appointment
July 19th Morning Report